The mission of the LuMind Research Down Syndrome Foundation is to stimulate biomedical research that will accelerate the development of treatments to significantly improve cognition, including memory, learning and speech,for individuals with Down syndrome.
Real LifeWhat if we could improve the learning ability of someone with Down syndrome by 15 percent? What new possibilities would open up at school, on the job, and in their ability to lead more active, independent lives? LuMind Foundation (formerly known as the Down Syndrome Research and Treatment Foundation - DSRTF) is funding groundbreaking scientific research to find a treatment to improve cognition including learning, memory and speech for individuals with Down syndrome. We currently fund research at six leading medical research institutions in the US including Stanford University and Johns Hopkins Medical Center.
Our approach led to breakthroughs in the identification of specific mechanisms responsible for cognitive impairment, new drug targets and several potential new drug candidates. In May 2014, Roche announced the initiation of a Phase II clinical trial, now ongoing, for a new drug candidate designed to address improving cognition and memory in people 12-30 years of age, with Down syndrome. Your support of our foundation and the researchers who made these breakthroughs contributed directly to these successes!